Neuroscience & Mental Health
Mental health View
- Almost half (45%) of Australians will experience a mental health disorder in their lifetime.
- Major programs of work with innovative approaches to small molecule drug discovery, tackling schizophrenia and cognitive disorders.
- Integrated drug discovery from structural biology to clinically-relevant animal models of disease.
- 40% of early retirements are due to chronic pain
- One in five initial GP appointments are due to pain and over three million Australians live with chronic pain
- The TPA involves integrated multidisciplinary research programs investigating:
- mechanisms of pain signalling
- novel drug targets, interventions and agents
- design of more effective and safer pain medications
- optimisation of safe and effective use of pain relief medicines, including opioids that are associated with abuse
Dementia and neurodegeneration View
- Neurodegenerative disorders are a leading cause of death and a significant burden on community and healthcare services.
- In Australia, almost 1 in 10 people over 65 suffer from dementia.
- The TPA fosters interdisciplinary research to investigate the underlying pathology of neurodegenerative disorders and explore innovative therapeutic strategies to treat disease progression and cognitive symptoms
- Multi-national collaborative program (NeuroGEN) to optimize dementia medicines use
Cancer and the brain View
Drug discovery researchers from Monash University have uncovered new, and unexpected, information about ‘xanomeline’, a potential-first-in class drug currently progressing through Phase III clinical trials for the treatment of patients
The study found a perceived insufficiency of evidence was preventing support for widespread clinical implementation of psychedelics in Australia.
The team of researchers from CMUS at MIPS followed 19,601 people hospitalised with a first ischaemic stroke in Victoria from 2013-2017.
The University of Sydney led guidelines, also involving researchers from Monash University, recommend that clinicians develop personalised deprescribing plans from the beginning for any patient being prescribed opioids.
The Glyph technology was initially developed by Professor Chris Porter and his team at MIPS and exclusively licensed to PureTech Health in 2017.
A new study by CMUS researchers has found Australians living with dementia are potentially being overtreated for diabetes, despite clinical guidelines recommending a less stringent approach to treating diabetes for people with coexisting dementia.
Researchers from Monash University have published a Cochrane systematic review on tools to predict dementia in middle aged adults (45 - 65 years).
A study from Monash University has found the prevalence of psychotropic dispensing for Australian children and adolescents aged 18 years and younger was twice as high in 2021 than in 2013.